Prospective Huntington At Risk Observational Study (PHAROS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2008 by Huntington Study Group.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Information provided by:
Huntington Study Group
ClinicalTrials.gov Identifier:
NCT00052143
First received: January 23, 2003
Last updated: April 15, 2009
Last verified: February 2008
  Purpose

The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.


Condition
Huntington Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Huntington At Risk Observational Study (PHAROS)

Resource links provided by NLM:


Further study details as provided by Huntington Study Group:

Biospecimen Retention:   Samples With DNA

Blood sample


Enrollment: 1001
Study Start Date: July 1999
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Huntington's disease (HD) is a genetic disease characterized by changes in movement and behavior. To date, little research has been done on individuals who are at risk for developing the disease. PHAROS is an observational study designed to monitor people who are at risk for developing HD, and to survey their attitudes and beliefs about their "at-risk" status. Investigators hope this study will help answer some important questions about HD, such as: 1.) What are the earliest signs of HD and when do they start? 2.) How accurate are the measures that physicians use in detecting the onset of HD? 3.) What factors influence the age at which a person carrying the HD gene develops the illness? and 4.) In a group of people at risk for HD, how many will develop signs of the illness over a minimum three-year period of observation?

Participants in the study will be evaluated every 9 months (for 5 years) using the Unified Huntington's Disease Rating Scale (UHDRS)--a clinical tool which looks at movement, psychological and behavioral function. The participants will also be asked to complete surveys about their mood, life events, and attitudes or beliefs about being at risk for HD. A blood sample, taken at the beginning of the study, will be confidentially tested to determine if the participant has the abnormal gene for HD. Neither the participant nor any of the PHAROS physicians or coordinators will learn the results of individual gene tests.

The scientists hope that this study will provide essential information for future trials of experimental drugs for HD.

  Eligibility

Ages Eligible for Study:   26 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

HD Community

Criteria

Inclusion:

  • Men and women between 26-55 years of age;
  • Who are at risk for HD by virtue of having (or had) a parent or sibling with the illness;
  • Who have never been tested for the HD gene, and who do not desire to be tested for the HD gene during the duration of the study;
  • Agree to blinded (sample will be coded) genetic testing of the HD gene; and
  • Who have never been diagnosed with HD.

Exclusion:

Individuals Who:

  • have been diagnosed with HD;
  • are taking antipsychotic medications;
  • use antiemetic (anti-nausea) medications with on a regular basis (greater than 3 times per month); or
  • exhibit clinical signs/symptoms of psychosis at the screening visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00052143

  Hide Study Locations
Locations
United States, Alabama
University of Alabama
Birmingham, Alabama, United States
United States, Arizona
Mayo Clinic Arizona
Phoenix, Arizona, United States
United States, California
University of California at San Diego
LaJolla, California, United States
UCLA School of Medicine
Los Angeles, California, United States
University of California, Davis
Sacramento, California, United States
United States, Colorado
Colorado Neurological Institute
Englewood, Colorado, United States
United States, Connecticut
University of Connecticut
Hartford, Connecticut, United States
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
United States, Florida
University of Miami School of Medicine
Miami, Florida, United States
University of South Florida
Tampa, Florida, United States
United States, Georgia
Emory University
Atlanta, Georgia, United States
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States
United States, Iowa
University of Iowa
Iowa City, Iowa, United States
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States
Hereditary Neurological Disease Center
Wichita, Kansas, United States
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States
University of Maryland at Baltimore
Baltimore, Maryland, United States
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States
Boston University School of Medicine
Boston, Massachusetts, United States
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States
United States, Minnesota
Hennepin County Medical Center
Minneapolis, Minnesota, United States
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States
United States, New Jersey
UMDNJ Huntington Disease Service Center
Stratford, New Jersey, United States
United States, New York
Albany Medical College
Albany, New York, United States
North Shore-LIJ Health System
Manhasset, New York, United States
Columbia University
New York, New York, United States
University of Rochester
Rochester, New York, United States
United States, North Carolina
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
United States, Ohio
Ohio State University
Columbus, Ohio, United States
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Rhode Island
NeuroHealth Parkinson's Disease Movement Disorders Center
Pawtucket, Rhode Island, United States
United States, Texas
Baylor College of Medicine
Houston, Texas, United States
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States
United States, Washington
University of Washington and VA Puget Sound
Seattle, Washington, United States
United States, Wisconsin
Medical College of Wisconsin-Milwaukee
Milwaukee, Wisconsin, United States
Canada, Alberta
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Canada, British Columbia
University of British Columbia
Vancouver, British Columbia, Canada
Canada, Ontario
The Centre for Addiction and Mental Health
Markham, Ontario, Canada
Canada, Quebec
Hotel-Dieu Hospital-CHUM
Montreal, Quebec, Canada
Sponsors and Collaborators
Huntington Study Group
Investigators
Principal Investigator: Ira Shoulson, M.D. University of Rochester
  More Information

Additional Information:
Publications:
Responsible Party: Ira Shoulson, MD, Professor of Neurology, University of Rochester
ClinicalTrials.gov Identifier: NCT00052143     History of Changes
Other Study ID Numbers: R01HG02449
Study First Received: January 23, 2003
Last Updated: April 15, 2009
Health Authority: United States: Federal Government

Keywords provided by Huntington Study Group:
Huntington's disease
HD
Huntington disease

Additional relevant MeSH terms:
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Dementia
Chorea
Dyskinesias
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 21, 2014